Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [21] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
    Bell, Andrew S.
    Wagner, Josephin
    Rosoff, Daniel B.
    Lohoff, Falk W.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2023, 149
  • [22] Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
    Leander, Karin
    Malarstig, Anders
    van't Hooft, Ferdinand M.
    Hyde, Craig
    Hellenius, Mai-Lis
    Troutt, Jason S.
    Konrad, Robert J.
    Ohrvik, John
    Hamsten, Anders
    de Faire, Ulf
    CIRCULATION, 2016, 133 (13) : 1230 - 1239
  • [23] Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease
    Blumenthal, Daniel M.
    Maddox, Thomas M.
    Aragam, Krishna
    Sacks, Chana A.
    Virani, Salim S.
    Wasfy, Jason H.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2021, 14 (09): : E007237
  • [24] Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review
    Shahid, Rabia
    Naik, Shaili S.
    Ramphall, Shivana
    Rijal, Swarnima
    Prakash, Vishakh
    Ekladios, Heba
    Saju, Jiya Mulayamkuzhiyil
    Mandal, Naishal
    Kham, Nang I.
    Hamid, Pousette
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [25] Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future
    Mansoor, Taha
    Rao, Bassam Hamid
    Gupta, Kartik
    Parikh, Sachin S.
    Abramov, Dmitry
    Mehta, Anurag
    Al Rifai, Mahmoud
    Virani, Salim S.
    Nambi, Vijay
    Minhas, Abdul Mannan Khan
    Koshy, Santhosh K. G.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2025, 25 (03) : 293 - 306
  • [26] Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis
    Lu, Xinjie
    CURRENT DRUG TARGETS, 2019, 20 (10) : 1029 - 1040
  • [27] Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
    Bhattacharya, Anindita
    Chowdhury, Abhirup
    Chaudhury, Koel
    Shukla, Praphulla Chandra
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (01):
  • [28] Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance
    Davidson, Erica R.
    Snider, Melissa J.
    Bartsch, Kelly
    Hirsch, Andrea
    Li, Junan
    Larry, John
    JOURNAL OF PHARMACY PRACTICE, 2020, 33 (03) : 276 - 282
  • [29] Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9): A new approach in lipid lowering treatment
    Klouras, E.
    Liberopoulos, E.
    Elisaf, M.
    ARCHIVES OF HELLENIC MEDICINE, 2015, 32 (01): : 77 - 84
  • [30] Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
    Cammisotto, Vittoria
    Baratta, Francesco
    Simeone, Paola G.
    Barale, Cristina
    Lupia, Enrico
    Galardo, Gioacchino
    Santilli, Francesca
    Russo, Isabella
    Pignatelli, Pasquale
    ANTIOXIDANTS, 2022, 11 (03)
12345